Cabozantinib (Thyroid Cancer)

Name: Cabozantinib (Thyroid Cancer) Drug Interactions
Creator: Dr. Brian Staiger, PharmD, BCPS

90 interactions 301 cited references

Also sold as: Cabometyx Cometriq Cometriq®

About Cabozantinib (Thyroid Cancer)

Cabozantinib (Cometriq) is used to treat a certain type of thyroid cancer that is getting worse and that has spread to other parts of the body. Cabozantinib (Cometriq) is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to mult… Read the full Cabozantinib (Thyroid Cancer) drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Dengue Tetravalent Vaccine, Live Ensitrelvir Measles Virus Vaccine, Live Mumps Virus Vaccine, Live Rubella Virus Vaccine, Live Yellow Fever Vaccine

10 Contraindicated 75 Major 5 Moderate

All (90) Contraindicated (10) Major (75) Moderate (5)

Major

Cabozantinib (Thyroid Cancer) Thioridazine Reduced cabozantinib exposure and reduced efficacy of cabozantinib Details Cabozantinib (Thyroid Cancer) Troleandomycin Increased cabozantinib exposure and an increased risk of cabozantinib-related adverse reactions Details Cabozantinib (Thyroid Cancer) Tucatinib Tukysa Increased cabozantinib exposure and an increased risk of cabozantinib-related adverse reactions Details Cabozantinib (Thyroid Cancer) Voriconazole Vfend Increased cabozantinib exposure and an increased risk of cabozantinib-related adverse reactions Details Cabozantinib (Thyroid Cancer) Warfarin Coumadin Increased risk of bleeding Details

Moderate

Cabozantinib (Thyroid Cancer) Artemether Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Cabozantinib (Thyroid Cancer) Kratom Increased CYP3A substrate exposure Details Cabozantinib (Thyroid Cancer) Levothyroxine Ermeza Increased risk of hypothyroidism Details Cabozantinib (Thyroid Cancer) Mavacamten Camzyos Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Cabozantinib (Thyroid Cancer) Rilzabrutinib Wayrilz Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.